A detailed history of Black Rock Inc. transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Black Rock Inc. holds 10,675,963 shares of XFOR stock, worth $7.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,675,963
Previous 8,735,867 22.21%
Holding current value
$7.47 Million
Previous $12.1 Million 49.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.58 - $1.47 $1.13 Million - $2.85 Million
1,940,096 Added 22.21%
10,675,963 $6.19 Million
Q1 2024

May 10, 2024

BUY
$0.72 - $1.46 $229,206 - $464,780
318,343 Added 3.78%
8,735,867 $12.1 Million
Q4 2023

Feb 13, 2024

BUY
$0.61 - $0.99 $159,016 - $258,076
260,683 Added 3.2%
8,417,524 $7.07 Million
Q3 2023

Nov 13, 2023

SELL
$1.03 - $2.02 $966,585 - $1.9 Million
-938,433 Reduced 10.32%
8,156,841 $8.89 Million
Q2 2023

Aug 11, 2023

BUY
$0.82 - $2.49 $7.18 Million - $21.8 Million
8,751,694 Added 2547.21%
9,095,274 $17.6 Million
Q1 2023

May 12, 2023

BUY
$0.8 - $1.22 $55,115 - $84,050
68,894 Added 25.08%
343,580 $298,000
Q4 2022

Feb 13, 2023

SELL
$0.69 - $2.21 $10,140 - $32,480
-14,697 Reduced 5.08%
274,686 $271,000
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.71 $10,617 - $20,400
11,930 Added 4.3%
289,383 $494,000
Q2 2022

Aug 12, 2022

BUY
$0.88 - $1.91 $4,979 - $10,808
5,659 Added 2.08%
277,453 $268,000
Q1 2022

May 12, 2022

SELL
$1.48 - $2.58 $4,075 - $7,105
-2,754 Reduced 1.0%
271,794 $476,000
Q4 2021

Feb 10, 2022

BUY
$1.9 - $5.6 $11,586 - $34,148
6,098 Added 2.27%
274,548 $628,000
Q3 2021

Nov 09, 2021

BUY
$4.53 - $6.45 $23,374 - $33,282
5,160 Added 1.96%
268,450 $1.42 Million
Q2 2021

Aug 11, 2021

BUY
$6.49 - $9.56 $1.71 Million - $2.52 Million
263,290 New
263,290 $1.71 Million

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $48.1M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.